OBJECTIVE — To investigate the efficacy of orlistat on the maintenance of weight loss over
3 years following a major weight loss induced by very-low-energy diet (VLED) in obese patients
with metabolic risk factors such as dyslipidemia, impaired fasting glucose, and diet-treated type
2 diabetes